Jane Street Group LLC Buys 110,572 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Jane Street Group LLC boosted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 37.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 406,766 shares of the medical instruments supplier's stock after buying an additional 110,572 shares during the quarter. Jane Street Group LLC owned approximately 0.55% of OraSure Technologies worth $1,468,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of OraSure Technologies by 202.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 5,234 shares during the period. Causeway Capital Management LLC bought a new stake in shares of OraSure Technologies during the fourth quarter worth approximately $36,000. Raymond James Financial Inc. acquired a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $37,000. Boothbay Fund Management LLC acquired a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $42,000. Finally, AXQ Capital LP bought a new position in shares of OraSure Technologies during the fourth quarter worth approximately $51,000. Institutional investors and hedge funds own 93.50% of the company's stock.

Analysts Set New Price Targets

OSUR has been the subject of several research reports. Wall Street Zen raised OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI reissued an "in-line" rating and set a $3.00 target price on shares of OraSure Technologies in a report on Monday, May 19th.

OraSure Technologies Price Performance

OraSure Technologies stock traded down $0.05 during midday trading on Friday, hitting $2.52. The company's stock had a trading volume of 700,344 shares, compared to its average volume of 857,351. The company has a market cap of $188.50 million, a price-to-earnings ratio of 16.80 and a beta of 0.42. OraSure Technologies, Inc. has a 1-year low of $2.36 and a 1-year high of $4.98. The company has a 50-day moving average price of $2.99 and a two-hundred day moving average price of $3.50.

OraSure Technologies declared that its Board of Directors has approved a stock repurchase plan on Monday, March 24th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 15.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

Insider Transactions at OraSure Technologies

In related news, CEO Manner Carrie Eglinton bought 78,625 shares of OraSure Technologies stock in a transaction dated Thursday, February 27th. The shares were bought at an average cost of $3.15 per share, with a total value of $247,668.75. Following the acquisition, the chief executive officer now owns 1,259,664 shares in the company, valued at $3,967,941.60. This trade represents a 6.66% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director John P. Kenny purchased 47,659 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the transaction, the director now directly owns 70,915 shares of the company's stock, valued at $224,800.55. This trade represents a 204.93% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 190,284 shares of company stock valued at $600,348. 3.90% of the stock is currently owned by company insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.